Editorial: chronic DILI and HILI—corticosteroid plus glycyrrhizin as standard therapy? Authors' reply

Jia‐Bo Wang,Ang Huang,Yijin Wang,Dong Ji,Zhengsheng Zou

DOI: https://doi.org/10.1111/apt.16983

2022-06-12

Abstract:Alimentary Pharmacology & Therapeutics, Volume 56, Issue 1, Page 168-169, July 2022.

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial

Jia‐Bo Wang,Ang Huang,Yijin Wang,Dong Ji,Qing‐Sheng Liang,Jun Zhao,Guangde Zhou,Shuhong Liu,Ming Niu,Ying Sun,Hui Tian,Guang‐Ju Teng,Bin‐Xia Chang,Jing‐Feng Bi,Xiao‐Xia Peng,Shaojie Xin,Huan Xie,Xiong Ma,Yi‐Min Mao,Suthat Liangpunsakul,Romil Saxena,Guruprasad P. Aithal,Xiao‐He Xiao,Jingmin Zhao,Zhengsheng Zou

DOI: https://doi.org/10.1111/apt.16902

2022-03-31

Abstract:SummaryBackgroundTreatment of chronic drug‐induced liver injury (DILI) or herb‐induced liver injury(HILI) is an important and unresolved challenge. There is no consensus regarding the indications for corticosteroids for chronic DILI/HILI.AimsTo investigate the efficacy and safety of corticosteroid plus glycyrrhizin for patients with chronic DILI/HILI.MethodsThis was a randomised open‐label trial. Eligible patients with causality assessment using the updated RUCAM were randomly assigned (1:1) either to the steroid treatment group (48‐week stepwise dose reduction of methylprednisolone plus glycyrrhizin) or control group (glycyrrhizin alone). Liver biopsies were performed at baseline and at the end of the 48‐week treatment period. The primary outcome was the proportion of patients with sustained biochemical response (SBR). The secondary outcomes were improvement in liver histology, time to biochemical normalisation and safety.ResultsOf 80 participants, 70 (87.5%) completed the trial. The patients were predominantly female (77.5%), aged >40 years (77.5%) and had a hepatocellular injury pattern of DILI (71.2%). Compared to the control group, the treatment group showed a higher proportion of SBR (94.3% vs. 71.4%, p = 0.023), shorter biochemical normalisation time and histological improvements in both histological activity and fibrosis. The DILI and HILI subgroups, as well as the autoimmune hepatitis (AIH)‐like DILI and non‐AIH‐like subgroups, showed comparable responses. No severe adverse events were observed during the trial.ConclusionThis study provides the first clinical evidence that corticosteroid plus glycyrrhizin therapy for chronic DILI with or without AIH‐like features can achieve both biochemical response and histological improvements with good safety. (ClinicalTrials.gov, NCT 02651350).

pharmacology & pharmacy,gastroenterology & hepatology
An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

Yao Lvfeng,Zhang Jianzhong,Jin Jie,Li Hongbin,Li Lei,Han Xian,Raza Hafiz Khuram,Li Xiaoyun,Mao Yimin

DOI: https://doi.org/10.1007/s11096-022-01402-x

IF: 2.305

2022-01-01

International Journal of Clinical Pharmacy

Abstract:Background Drug-induced liver injury (DILI) refers to liver damage caused by drugs. DILI poses a significant challenge in the development of new drugs. The management of DILI mainly involves the withdrawal of the offending drug, and there is a lack of specific therapy. This study sought to evaluate the efficacy and safety of compound glycyrrhizin (CG) injections in DILI patients. Aim To evaluate the efficacy and safety of compound glycyrrhizin injections in DILI treatment. Methods The clinical data of DILI patients were collected from a nationwide DILI database. Patients were divided into two groups: the compound glycyrrhizin (CG) group who received CG injections, and the control group who received no treatment. The propensity score matching (PSM) method was applied to obtain an even distribution of characteristics between the two groups. The efficacy of the CG injections was assessed by the analysis of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels between the two groups. Results There were 152 patients in the compound glycyrrhizin group and 512 patients in the control group. The PSM method was used to acquire 152 matched pairs. The compound glycyrrhizin group had a significantly higher overall ALT and AST normalization rate than the control group (43.42% vs. 24.34%, p = 0.0004 and 63.82% vs. 38.82%, p ≤ .0001). There was no difference in the levels of renal and serum biochemical parameters between the two groups. Conclusions CG injections are effective in reducing ALT and AST levels in DILI patients, and their safety is comparable to the control group.
An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial

Ang Huang,Yun Zhu,Shuhong Liu,Ying Sun,Zherui Liu,Qing‐sheng Liang,Jun Zhao,Bin‐xia Chang,Jing‐feng Bi,Jiang‐tao Liu,Xing‐ran Zhai,Huan Xie,Ning Li,Hui Tian,Lin Han,Yingjie Zhuang,Hongbin Ma,Guang‐ju Teng,Wei Zhang,Guruprasad P. Aithal,Dong Ji,Jingmin Zhao,Zhengsheng Zou

DOI: https://doi.org/10.1111/liv.15899

IF: 8.754

2024-03-15

Liver International

Abstract:Background and Aims The use of corticosteroids in chronic drug‐induced liver injury (DILI) is an important issue. Our previous randomized controlled trial showed that patients with chronic DILI benefited from a 48‐week steroid stepwise reduction (SSR) regimen. However, it remains unclear whether a shorter course of therapy can achieve similar efficacy. In this study, we aimed to assess whether a 36‐week SSR can achieve efficacy similar to that of 48‐week SSR. Methods A randomized open‐label trial was performed. Eligible patients were randomly assigned to the 36‐ or 48‐week (1:1) SSR group. Liver biopsies were performed at baseline and at the end of treatment. The primary outcome was the proportion of patients with relapse rate (RR). The secondary outcomes were improvement in liver histology and safety. Results Of the 90 participants enrolled, 84 (87.5%) completed the trial, and 62 patients (68.9%) were women. Hepatocellular damage was observed in 53.4% of the cohort. The RR was 7.1% in the 36‐week SSR group but 4.8% in the 48‐week SSR group, as determined by per‐protocol set analysis (p = 1.000). Significant histological improvements in histological activity (93.1% vs. 92.9%, p = 1.000) and fibrosis (41.4% vs. 46.4%, p = .701) were observed in both the groups. Biochemical normalization time did not differ between the two groups. No severe adverse events were observed. Conclusions Both the 36‐ and 48‐week SSR regimens demonstrated similar biochemical response and histological improvements with good safety, supporting 36‐week SSR as a preferable therapeutic choice (ClinicalTrials.gov, NCT03266146).

gastroenterology & hepatology
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply

Kwan‐Lung Ko,Ivan Fan‐Ngai Hung,Wai K. Leung

DOI: https://doi.org/10.1111/apt.17069

2022-06-26

Abstract:Alimentary Pharmacology & Therapeutics, Volume 56, Issue 2, Page 355-356, July 2022.

pharmacology & pharmacy,gastroenterology & hepatology
Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?

Morven Cunningham

DOI: https://doi.org/10.1111/apt.17911

IF: 9.524

2024-03-12

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 7, Page 905-906, April 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury

Huanyu Wu,Wanping Yan,Ke Liu,Jisheng Jing,Wei Ye

DOI: https://doi.org/10.1016/j.clinre.2024.102472

Abstract:Background and aim: There is no conventional treatment for patients with severe drug-induced liver injury (DILI) except for discontinuation of liver injury drugs and symptomatic supportive therapy. Opinions on whether corticosteroids can be used to treat severe DILI are conflicting, and most of the relevant clinical studies are case reports or retrospective studies, which still need to be supported by high-level evidence-based medical studies. This study aimed to evaluate the effect and tolerance of corticosteroids in patients with severe DILI. Risk factors associated with patient failure to cure were also explored. Methods: Propensity score matching based on nearest-neighbor 1:1 matching was used to screen severe DILI patients in the corticosteroids and control groups. Severe DILI was defined as elevated serum ALT and/or ALP with TBIL≥5 ULN (5 mg/dL or 85.5 μmol/L) with or without INR ≥1.5. Patients were treated with conventional therapy combined with corticosteroids in the corticosteroids group and only conventional therapy in the control group. Results: A total of 146 patients, 73 each in the corticosteroids and control groups, were included in this study. By analyzing the entire cohort, we found no significant difference in cure rates between patients in the corticosteroid group and control group (34.2% vs. 20.5 %, p = 0.095), and there was no significant difference in the incidence of adverse effects between the two groups (20.5% vs. 20.5 %, p = 1.000). However, TBIL decreased more in the corticosteroids group on day 7 (89.2 ± 107.6 μmol/L vs. 58.8 ± 70.7 μmol/L, p = 0.046). In subgroup analyses, patients whose TBIL remained elevated despite conventional treatment had a higher TBIL decline on day 7,14 after use of corticosteroid (99.2 ± 98.5μmol/L vs. -23.3 ± 50.4μmol/L, p < 0.001; 120 ± 119.1μmol/L vs. 61.2 ± 98.5μmol/L, p = 0.047). The cure rate of patients in the corticosteroid group was significantly higher than that of the control group (36.1 % versus 4.5 %, p = 0.016). The proportion of patients with TBIL <85.5 μmol/L was also significantly higher in the corticosteroid group than in the control group at day 7 (p = 0.016) and day 14 (p = 0.004) after treatment. In the subgroup analysis of patients with different clinical phenotypes, the causative agent was herbal, autoimmune antibody-positive and 40 % < PTA ≤ 50 % of patients, corticosteroid use did not increase the cure rate of the patients. Univariate and multifactorial analyses found corticosteroid use to be a protective factor for failure to cure in patients with severe DILI (p < 0.001, OR:0.191,95 % CI:0.072-0.470), and peak TBIL to be a risk factor (p = 0.003, OR:1.016,95 % CI:1.007-1.028). Conclusions: The addition of corticosteroids could not increase the cure rate in patients with severe DILI, but it could rapidly reduce the patient's TBIL at an earlier stage. Corticosteroids could also promote curing in patients with elevated TBIL after conventional treatment. Corticosteroid use was a protective factor for failure to cure in patients with severe DILI and peak TBIL was a risk factor.
Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review

Punan Wang,Guanya Guo,Shuangshuang Jiang,Dawei Ding,Jiaqi Yang,Yi Lu,Ying Han,Xinmin Zhou

DOI: https://doi.org/10.1007/s11033-024-09806-w

2024-07-31

Abstract:Drug-induced liver injury (DILI) is an adverse reaction to drugs and their metabolites. The activation of adaptive immune and inflammatory responses plays an important role in the pathogenesis of DILI. Glucocorticoids (GCs) have powerful anti-inflammatory and immunosuppressive effects and have been used to treat a variety of immune-mediated liver diseases. Due to the important role of the immune system in DILI, GCs are widely used in the clinical treatment of DILI; however, whether they are beneficial to patients remains controversial. There is no uniform standard for the timing, dosage, and population selection of GCs, which mainly depend on the clinician's experience. Therefore, elucidating whether GCs are beneficial for patients with DILI is an urgent clinical problem. Our review summarizes the recent literature and discusses the clinical efficacy, applicable population, application timing, and efficacy of GCs in special types of DILI, providing a reference for the clinical application of GCs.
Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

Lingya Yao,Haotian Chen,Bule Shao,Jing Liu,Chaohui Wang,Zhou Zhang,Qian Cao

DOI: https://doi.org/10.1093/ibd/izab327

2022-01-01

Inflammatory Bowel Diseases

Abstract:Background The temporal trends in medical treatment and long-term outcomes of patients with Crohn's disease (CD) have not been well elucidated in China over the past 2 decades. Accordingly, we aimed to evaluate the treatment paradigm and long-term clinical course of Chinese patients with CD in a hospital-based cohort. Methods All adult patients newly diagnosed with CD (n = 1338) between 1999 and 2019 in the Sir Run Run Shaw Hospital were included in this cohort. Medication utilization, disease outcomes, and risk factors were investigated. Results Overall, 48.7%, 35.6%, 67.8%, and 61.6% of patients used 5-aminosalicylates (5-ASA), corticosteroids, thiopurines, and infliximab (IFX), respectively. The cumulative risk of 5-ASA and corticosteroid initiation decreased during follow-up, whereas that of IFX initiation increased. Throughout a median follow-up duration of 26.4 (interquartile range, 12.0-49.2) months, a total of 486 and 300 patients underwent hospitalization and surgery, respectively. Of the 1097 patients with B1/B2 disease behavior at diagnosis, 10.3% experienced phenotype progression. The hospitalization rate decreased after 2015; however, surgery and phenotype progression rates did not significantly change. A Cox regression analysis indicated that IFX use since diagnosis was a contributing factor for lower rates of hospitalization and phenotype progression, whereas thiopurine use was associated with a lower surgery rate. Conclusions Infliximab use was observed to increase as 5-ASA and corticosteroid use decreased. Additionally, hospitalization rates decreased following temporal changes in IFX management, yet the surgery and phenotype progression rates remained the same.
Current Use of Immunosuppressive Agents in Inflammatory Bowel Disease Patients in East China

Li-Juan Huang,Qin Zhu,Min Lei,Qian Cao

DOI: https://doi.org/10.3748/wjg.15.3055

2009-01-01

Abstract:AIM: To investigate immunosuppressive agents used to treat inflammatory bowel disease (IBD) in East China.METHODS: A retrospective review was conducted, involving 227 patients with IBD admitted to Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University from June 2000 to December 2007. Data regarding demographic, clinical characteristics and immunosuppressants usage were analyzed.RESULTS: A total of 227 eligible patients were evaluated in this study, including 104 patients with Crohn's disease and 123 with ulcerative colitis. Among the patients, 61 had indications for immunosuppressive agents use. However, only 21 (34.4%) received immunosuppressive agents. Among the 21 patients, 6 (37.5%) received a subtherapeutic dose of azathioprine with no attempt to increase the dosage. Of the 20 patients that received immunosuppressive agent treatment longer than 6 mo, 15 patients went into remission, four patients were not affected and one relapsed. Among these 20 patients, four patients suffered from myelotoxicity and one suffered from hepatotoxicity.CONCLUSION: Immunosuppressive agents are used less frequently to treat IBD patients from East China compared with Western countries. Monitoring immunosuppressive agent use is recommended to optimize dispensation of drugs for IBD in China. (c) 2009 The WJG Press and Baishideng. All rights reserved.
Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply

Tomohiro Fukuda,Hajime Yamazaki,Katsuyoshi Matsuoka

DOI: https://doi.org/10.1111/apt.18111

IF: 9.524

2024-06-09

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Fukuda et al papers. To view these articles, visit https://doi.org/10.1111/apt.18013 and https://doi.org/10.1111/apt.18094

pharmacology & pharmacy,gastroenterology & hepatology
Features and Outcomes from a Retrospective Study of 570 Hospitalized Chinese Patients with Drug-Induced Liver Injury.

Lili Pang,Wanna Yang,Fengqin Hou

DOI: https://doi.org/10.1016/j.clinre.2017.08.003

IF: 3.189

2018-01-01

Clinics and Research in Hepatology and Gastroenterology

Abstract:Aims: To investigate the clinical features and outcomes of hospitalized patients with drug induced liver injury (DILI). Methods: The medical records of hospitalized patients with DILI from January 1997 through July 2016 were reviewed. Results: Five hundred seventy cases were reviewed, of which 381 (66.8%) were female. Four hundred fifty-eight cases (80.4%) presented with hepatocellular injury, 53 (9.3%) with cholestatic injury and 59 (10.4%) with mixed injury. Chronicity was more common in cholestatic and mixed injury cases than in hepatocellular cases (P<0.001). In the hepatocellular injury group, patients in the severity score >= 3 group were younger than the patients in the severity score <= 2 group (P=0.040). In the entire cohort, 487/570 (85.4%) patients resolved, 57/570 (10.0%) developed chronic liver injury, and 11/570 (1.9%) died. Thirty-two acute DILI patients with severity scores of 3 received steroid therapy, but no improvement was observed in the recovery time or resolution rate of these patients compared with that of the non-steroid group. Chinese herbal medicines were the most commonly used drugs, followed by antimicrobials, cardiovascular agents, endocrine agents, and nonsteroidal anti-inflammatory drugs (NSAIDs). Conclusions: Hepatocellular injury was the most common DILI pattern, and 10.0% of patients developed chronic DILI. Steroid therapy was not associated with an improved recovery time or survival in acute severe DILI patients. (C) 2017 Published by Elsevier Masson SAS.
Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis?

Elton Dajti,Susana G. Rodrigues

DOI: https://doi.org/10.1111/apt.17943

IF: 9.524

2024-04-25

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 10, Page 1286-1287, May 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Editorial: when to start carvedilol in cirrhosis—time to reconsider? Authors' reply

Karn Wijarnpreecha,Fang Li,C. Burcin Taner,Liu Yang,Cui Tao

DOI: https://doi.org/10.1111/apt.16526

2021-08-11

Abstract:This article is linked to Wijarnpreecha et al and Gillespie & Hayes papers. To view these articles, visit https://doi.org/10.1111/apt.16490 and https://doi.org/10.1111/apt.16512

pharmacology & pharmacy,gastroenterology & hepatology
Successful corticosteroid therapy for severe liver injury secondary to herbal traditional Chinese medicine, Mega Defends X, assessed for causality by the updated RUCAM: A case report

Lu Chai,Ran Wang,Rolf Teschke,Shenghao Jin,Jiao Deng,Xingshun Qi

DOI: https://doi.org/10.1097/md.0000000000039439

IF: 1.6

2024-08-29

Medicine

Abstract:As the key metabolic center of chemical ingredients found in herbal products, the liver is particularly susceptible to adverse toxic reactions including herb-induced liver injury (HILI). [ 1 ] In a Chinese retrospective study on 1985 drug-induced liver injury (DILI) and HILI cases observed between 2009 and 2014, as much as 563 cases (28.4%) were HILI. [ 2 ] Once HILI is diagnosed, suspected herbs should be withdrawn according to the current practice guidelines. [ 3 ] Most of patients will recover spontaneously within 6 months of herb withdrawal. However, some patients will progress to chronic liver injury, acute liver failure (ALF), and even death. [ 4 ] A meta-analysis found that 1.5% of the 936 cases with confirmed HILI developed chronic liver injury and 10.4% died. [ 5 ]

medicine, general & internal
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply

Abhinav Vasudevan,Danny Con,Daniel R. Langenberg,Daniel R. van Langenberg

DOI: https://doi.org/10.1111/apt.17895

IF: 9.524

2024-02-26

Alimentary Pharmacology & Therapeutics

Abstract:Alimentary Pharmacology &Therapeutics, Volume 59, Issue 6, Page 794-794, March 2024.

pharmacology & pharmacy,gastroenterology & hepatology
Therapeutic potential of traditional Chinese medicine for interstitial lung disease

Yan-Ming Zhou,Xin-Ran Dong,Dong Xu,Jie Tang,Yuan-Lu Cui

DOI: https://doi.org/10.1016/j.jep.2023.116952

2024-01-10

Abstract:Ethnopharmacological relevance: Interstitial lung disease (ILD) is a chronic lung dysfunction disease with a poor prognosis and poor recovery. The clinically used therapeutic drugs, such as glucocorticoids and immunosuppressants, have no significant therapeutic effect and are accompanied with severe side effects. In recent years, considerable progress has been made in exploring and applying natural herb components for treating ILD. Traditional Chinese Medicine (TCM) possesses innate, non-toxic characteristics and offers advantages in preventing and treating pulmonary ailments. However, a comprehensive study of TCM on ILD therapy has not yet been reviewed. Aim of the review: This review aimed to provide a comprehensive summary of the monomer components, total extracts, and prescriptions of TCM for ILD therapy, elucidating their molecular mechanisms to serve as a reference in treating ILD. Materials and methods: The literature information was searched in the PubMed, Web of Science databases. The search keywords included 'interstitial lung disease', 'lung fibrosis' or 'pulmonary fibrosis', and 'traditional Chinese medicine', 'traditional herbal medicine', or 'herb medicine'. Results: The active components of single herbs, such as alkaloids, flavonoids, terpenoids, phenols, and quinones, have potential therapeutic effects on ILD. The active extracts and prescriptions were also summarized and analyzed. The herbs, Glycyrrhiza uralensis Fisch. (Gancao), Astragalus membranaceus Fisch. Bunge. (Huangqi) and Angelicasinensis (Oliv.) Diels (Danggui), play significant roles in the treatment of ILD. The mechanisms involve the inhibition of inflammatory factor release, anti-oxidative injury, and interference with collagen production, etc. CONCLUSION: This review examines the therapeutic potential of TCM for ILD and elucidates its molecular mechanisms, demonstrating that mitigating inflammation and oxidative stress, modulating the immune system, and promoting tissue repair are efficacious strategies for ILD therapy. The depth research will yield both theoretical and practical implications.
S4559 Successful Use of Corticosteroids to Accelerate Recovery in Severe Autoimmune-like Hepatitis From Isoniazid: A Case Report

Amir Sultan Seid,Oyedele Adeyi,Mary Thomson

DOI: https://doi.org/10.14309/01.ajg.0001047604.84215.2f

2024-10-26

The American Journal of Gastroenterology

Abstract:Corticosteroids have been used in some cases of drug-induced liver injury (DILI) to hasten recovery, although their efficacy remains controversial. We present a case of severe isoniazid (INH)-induced autoimmune-like hepatitis in which corticosteroid therapy was used to accelerate recovery following the discontinuation of INH.

gastroenterology & hepatology
Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Feng-Qin Hou,Zheng Zeng,Gui-Qiang Wang

DOI: https://doi.org/10.1007/s12013-012-9373-y

2012-01-01

Cell Biochemistry and Biophysics

Abstract:We investigated clinical features, therapy, and outcomes of patients hospitalized for drug-induced liver injury (DILI). DILI resolution was defined as liver biochemistry values back to normal or lower than CIOMS laboratory criteria; Chronicity was defined as persistent biochemical abnormality for >6 months after drugs’ withdrawal. Three-hundred cases were reviewed retrospectively; mean age 51 (13–86) years, and 204 (68 %) were females. It included 267 (89 %) hepatocellular injury, 16 (5.3 %) cholestatic injury, and 17 (5.7 %) mixed injury cases. In hepatocellular injury group, 197 (73.8 %) patients with TBIL < 10× ULN included 142 (72.1 %) females and 70 (26.2 %) patients with TBIL ≥ 10× ULN included 39 (55.7 %) females ( P = 0.012). Of 70 patients (TBIL ≥ 10× ULN), 20 were treated with steroid step-down therapy (79 ± 26 days) and others with non-steroid therapy. The steroid therapy group showed higher DILI resolution rate ( P = 0.029) and shorter recovery time ( P = 0.012). Notably, 274/300 (91.3 %) patients resolved, 18/300 (6 %) developed chronic liver injury, 7/300 (2.3 %) died, and one patient received liver transplantation. In death group, TBIL, ALB, PT, and PTA revealed more severe abnormality than in recovery group. In 121/300 (40.3 %) patients, use of herbal medicines was the leading cause of liver injury, followed by antibiotics, cardiovascular drugs, and endocrine drugs. We concluded that step-down steroid therapy for DILI improved curative effect, shortened disease course, and was safe.
Huang Lian Jie Du decoction attenuated colitis via suppressing the macrophage Csf1r/Src pathway and modulating gut microbiota

Shan Su,Ting Liu,Jia-Yi Zheng,Hai-Cui Wu,Vincent W Keng,Shi-Jie Zhang,Xiao-Xiao Li

DOI: https://doi.org/10.3389/fimmu.2024.1375781

2024-09-26

Abstract:Introduction: Ulcerative colitis, a subtype of chronic inflammatory bowel disease (IBD), is characterized by relapsing colonic inflammation and ulcers. The traditional Chinese herbal formulation Huang Lian Jie Du (HLJD) decoction is used clinically to treat diarrhea and colitis. However, the mechanisms associated with the effects of treatment remain unclear. This study aims to elucidate the molecular mechanistic effects of HLJD formulation on colitis. Methods: Chronic colitis in mice was induced by adding 1% dextran sulfate sodium (DSS) to their drinking water continuously for 8 weeks, and HLJD decoction at the doses of 2 and 4 g/kg was administered orally to mice daily from the second week until experimental endpoint. Stool consistency scores, blood stool scores, and body weights were recorded weekly. Disease activity index (DAI) was determined before necropsy, where colon tissues were collected for biochemical analyses. In addition, the fecal microbiome of treated mice was characterized using 16S rRNA amplicon sequencing. Results: HLJD decoction at doses of 2 and 4 g/kg relieved DSS-induced chronic colitis in mice by suppressing inflammation through compromised macrophage activity in colonic tissues associated with the colony-stimulating factor 1 receptor (Csf1r)/Src pathway. Furthermore, the HLJD formula could modify the gut microbiota profile by decreasing the abundance of Bacteroides, Odoribacter, Clostridium_sensu_stricto_1, and Parasutterella. In addition, close correlations between DAI, colon length, spleen weight, and gut microbiota were identified. Discussion: Our findings revealed that the HLJD formula attenuated DSS-induced chronic colitis by reducing inflammation via Csf1r/Src-mediated macrophage infiltration, as well as modulating the gut microbiota profile.
Effects of Yinzhihuang on Alleviating Cyclosporine A-Induced Cholestatic Liver Injury via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Vitro and in Vivo

Yanjie Qin,Jingxuan Tan,Xuemei Han,Nanxi Wang,Xuejia Zhai,Yongning Lu

DOI: https://doi.org/10.1248/bpb.b23-00580

Abstract:Yinzhihuang (YZH), a traditional Chinese medicine prescription, was widely used to treat cholestasis. Cholestatic liver injury limited the use of the immunosuppressive drug cyclosporine A (CsA) in preventing organ rejection after solid organ transplantation. Clinical evidences suggested that YZH could enhance bile acids and bilirubin clearance, providing a potential therapeutic strategy against CsA-induced cholestasis. Nevertheless, it remains unclear whether YZH can effectively alleviate CsA-induced cholestatic liver injury, as well as the molecular mechanisms responsible for its hepatoprotective effects. The purpose of the present study was to investigate the hepatoprotective effects of YZH on CsA-induced cholestatic liver injury and explore its molecular mechanisms in vivo and vitro. The results demonstrated that YZH significantly improved the CsA-induced cholestatic liver injury and reduced the level of liver function markers in serum of Sprague-Dawley (SD) rats. Targeted protein and gene analysis indicated that YZH increased bile acids and bilirubin efflux into bile through the regulation of multidrug resistance-associated protein 2 (Mrp2), bile salt export pump (Bsep), sodium taurocholate cotransporting polypeptide (Ntcp) and organic anion transporting polypeptide 2 (Oatp2) transport systems, as well as upstream nuclear receptors farnesoid X receptor (Fxr). Moreover, YZH modulated enzymes involved in bile acids synthesis and bilirubin metabolism including Cyp family 7 subfamily A member 1 (Cyp7a1) and uridine 5'-diphosphate (UDP) glucuronosyltransferase family 1 member A1 (Ugt1a1). Furthermore, the active components geniposidic acid, baicalin and chlorogenic acid exerted regulated metabolic enzymes and transporters in LO2 cells. In conclusion, YZH may prevent CsA-induced cholestasis by regulating the transport systems, metabolic enzymes, and upstream nuclear receptors Fxr to restore bile acid and bilirubin homeostasis. These findings highlight the potential of YZH as a therapeutic intervention for CsA-induced cholestasis and open avenues for further research into its clinical applications.

Editorial: chronic DILI and HILI—corticosteroid plus glycyrrhizin as standard therapy? Authors' reply

Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial

An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial

Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply

Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?

Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury

Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

Current Use of Immunosuppressive Agents in Inflammatory Bowel Disease Patients in East China

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply

Features and Outcomes from a Retrospective Study of 570 Hospitalized Chinese Patients with Drug-Induced Liver Injury.

Editorial: Are glucagon‐like peptide‐1 receptor agonists the functional cure for patients with metabolic dysfunction‐associated cirrhosis?

Editorial: when to start carvedilol in cirrhosis—time to reconsider? Authors' reply

Successful corticosteroid therapy for severe liver injury secondary to herbal traditional Chinese medicine, Mega Defends X, assessed for causality by the updated RUCAM: A case report

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply

Therapeutic potential of traditional Chinese medicine for interstitial lung disease

S4559 Successful Use of Corticosteroids to Accelerate Recovery in Severe Autoimmune-like Hepatitis From Isoniazid: A Case Report

Hospital Admissions for Drug-Induced Liver Injury: Clinical Features, Therapy, and Outcomes

Huang Lian Jie Du decoction attenuated colitis via suppressing the macrophage Csf1r/Src pathway and modulating gut microbiota

Effects of Yinzhihuang on Alleviating Cyclosporine A-Induced Cholestatic Liver Injury via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Vitro and in Vivo